Pancreatic Cancer Research

ResearcherMedical University of South CarolinaActive in the last 2 years

A. Craig Lockhart

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers
1
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 trial

Papers 1

  1. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗

Trials 1

  1. Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma Principal investigator NCT07076212↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Davendra P. S. Sohal · 1 shared paper, 2022 · strength 0.12
  2. Ibrahim Hanna Azar · 1 shared paper, 2022 · strength 0.12
  3. Andrew Eugene Hendifar · 1 shared paper, 2022 · strength 0.12
  4. Moh'd M. Khushman · 1 shared paper, 2022 · strength 0.12
  5. David B. Spetzler · 1 shared paper, 2022 · strength 0.12
  6. Michael J. Hall · 1 shared paper, 2022 · strength 0.12
  7. Emil Lou · 1 shared paper, 2022 · strength 0.12
  8. Wolfgang Michael Korn · 1 shared paper, 2022 · strength 0.12
  9. Jun Gong · 1 shared paper, 2022 · strength 0.12
  10. Wafik S. El‐Deiry · 1 shared paper, 2022 · strength 0.12
  11. Benjamin Adam Weinberg · 1 shared paper, 2022 · strength 0.12
  12. John Lindsay Marshall · 1 shared paper, 2022 · strength 0.12
  13. Anthony Frank Shields · 1 shared paper, 2022 · strength 0.12
  14. Philip A. Philip · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.